NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

NewAmsterdam Pharma said its key PREVAIL outcomes study is progressing on schedule or ahead of schedule, with the interim event-rate time point expected around the end of 2026 and the readout in Q1 2027. Management characterized the year as highly productive, but the article contains no trial results or financial updates. The update is constructive for the pipeline but remains largely preparatory and conference-based.

Analysis

The key market implication is not the interim itself, but the compression of uncertainty into a single catalyst window. Pulling the event threshold forward to year-end creates a binary setup for the stock over the next 2-3 quarters: volatility should stay bid into the event, while realized downside gets capped if investors believe the study is now closer to de-risking than a distant science project. The second-order effect is on funding conditions for the entire cardiometabolic/broad primary prevention bucket, where a credible readout can re-rate not just NAMS but adjacent names competing for capital and trial attention.

The hidden lever is options positioning and implied-vol structure. As the event window narrows, front-end IV should expand faster than the underlying drift, especially if management continues to signal schedule confidence without adding hard data. That creates an opportunity for investors who can tolerate mark-to-market noise: the market may pay up for convexity before fundamentals are fully visible, but will likely punish any hiccup in event-rate assumptions because the trial’s perceived cleanliness is more important than the precise timing.

Contrarianly, the consensus may be underestimating how much of the upside is already embedded in a “best case” path. For a large outcomes study, moving the analysis earlier can also raise the probability of an underpowered or noisier interim if event accumulation is less robust than hoped, which would delay the thesis rather than kill it. In other words, the trade is less about the first read and more about whether the company can avoid a credibility gap between now and the first-quarter catalyst.

On balance, this is a classic event-driven long with asymmetric downside if the interim disappoints and limited fundamental downside if the study merely remains on track. The best expression is likely through optionality or a structured long/short versus a slower-moving cardiometabolic peer set, rather than outright equity ahead of the catalyst.

Key Decisions for Investors

• Buy NAMS call spreads into the year-end event-rate window; target 3-5x payoff if the interim confirms de-risking, with defined loss if the catalyst is noisy or delayed.
• Go long NAMS / short a basket of late-stage cardiometabolic peers over the next 3-6 months to isolate trial-catalyst alpha and reduce market beta.
• If already long common, hedge into the catalyst with short-dated puts or collars; the setup favors upside convexity, but gap risk on a disappointing interim is material.
• Use any post-rally strength ahead of Q1 readout to trim 25-50% of common equity and re-enter on volatility spikes; the risk/reward is better on pullbacks than chasing into the announcement.